Four examples of patient care services that pharmacies can implement and why they can be beneficial to a pharmacy’s business model.
This study found no significant difference in the sustained return of spontaneous circulation or survival to hospital discharge based on the timing of the first epinephrine administration in these patients.
Previous studies have shown that individuals living with HIV are at higher risk for heart disease than individuals without HIV
The lingering effects of the COVID-19 pandemic, including supply concerns and staffing shortages, have made technological solutions become more crucial.
Multiple sclerosis is a debilitating disease affecting many Americans. Pharmacists can help patients control the symptoms that impact their quality of life.
Chemotherapy-induced nausea and vomiting can impact patients’ treatment outcomes.
Process helps prevent errors for individuals with chronic disorders who often have a higher risk of drug-drug interactions.
Rivaroxaban is the only FDA-approved anticoagulant used in patients with peripheral artery disease and coronary artery disease.
Legislative efforts regarding cybersecurity are ongoing, but individuals and organizations should remain vigilant.
Some devices are being sold OTC for individuals without diabetes to track their health.
Four examples of patient care services that pharmacies can implement and why they can be beneficial to a pharmacy’s business model.
Technicians with specialized skills in prescription billing can help pharmacists focus on clinical services.
Sacituzumab govitecan-hziy (Trodelvy) is indicated for the treatment of patients with triple-negative breast cancer who have received 2 prior therapies at minimum for metastatic disease.
Patient education and counseling play a critical role in preventing C. difficile recurrence, and pharmacists are uniquely positioned to provide treatment recommendations, educate patients and health care providers, optimize transitions of care, and reduce the risk of recurrent CDI.
Technicians can stay involved in the profession and connected with others after retirement
Diana Violanti, PharmD, and Pamela S. Moore, PharmD, BCGP, discuss the nuanced use of anticholinergic agents for managing terminal secretions at end of life, highlighting practical considerations, timing, safety concerns such as delirium, and the limited yet evolving evidence supporting their role in palliative care.
Although the anticonvulsant is not considered a controlled substance, some state legislation focuses on monitoring the use of or reclassifying it.
Be of value to patients and caregivers in forming a care plan for this challenging condition
Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses how looming tariffs, vaccine misinformation, and rising drug costs are straining public health pharmacy efforts, while also sparking new opportunities for innovation, collaboration, and community-centered care amid uncertainty.
Patient retraces her treatment journey from diagnosis through treatment for glioblastoma.
Promising data have emerged suggesting a significant weight loss benefit for patients using GLP-1 agonists and GLP-1/GIP dual agonists.
Empiric anti-MRSA therapy is an area of opportunity for antimicrobial stewardship in the treatment of CAP.
Treatment for RLS includes lifestyle modifications, medication, and in some cases, non-drug therapies, aiming to reduce symptoms and improve sleep and daytime functioning.
Expert provides a comprehensive overview of drug diversion prevention in pharmacy settings.
A panelist discusses how the 505(b)(2) regulatory pathway provides a streamlined approval process for modified versions of previously approved drugs, allowing pharmaceutical companies to rely partly on existing safety/efficacy data while still requiring new clinical data, commonly used across various therapeutic areas including reformulations, new dosage forms, and drug combinations.
Pharmacists are the premier medication experts within health care, who understand more about medication interactions than most physicians and have the unique ability to prevent complications, improve adherence, and save lives.
This medication is associated with a number of adverse effects, such as gastrointestinal upset and peripheral neuropathies, that may be mitigated by less frequent dosing.
Legislative efforts in the states and Washington, DC, have made progress, but there is still a way to go.